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OBJECTIVES: To examine cost to society due to underemployment among adults 
or parents of children (aged<18 years) with hemophilia A or B. METHODS: Data 
were obtained from HUGS Va and Vb, two multi-center cohort studies of persons 
with hemophilia A and B, respectively, who received comprehensive care at 
Hemophilia Treatment Centers in the United States. Underemployment, based 
on participants’ self-report, is defined as being employed part-time or 
unemployed due to hemophilia. Cost to society includes annualized aggregate 
earnings and non-wage benefits lost due to underemployment. The average 
hourly compensation rate was assumed to be US$30.80 based on the employer 
costs for employees’ compensation from the Bureau of Labor Statistics (2012). 
Part-time work was assumed to be 20 hours/week. Sensitivity analysis was 
conducted to determine the variation of cost by varying part-time work hours 
from 10 to 30 hours/week. RESULTS: Of 474 patients (329 hemophilia A), 275 
(58%) had severe hemophilia, of which 211 (64%) and 64 (44%) had hemophilia A 
and B, respectively. The number of adults or parents of children working full-
time, part-time or unemployed was 214 (45%), 96 (20%) and 163 (34%), 
respectively. Among the latter two groups, 24 (25%) part-time participants and 49 
(30%) unemployed participants attributed their employment status to 
hemophilia. Adults or parents of children with severe disease were more likely to 
be underemployed than those with mild/moderate disease (p=0.0002). The 
proportion of underemployed parents of children (12%) was comparable to that 
of underemployed adult patients (19%). Among the HUGS population, the 
estimated annual cost of underemployment to society due to hemophilia was 
US$3.91 million (range: $3.52-$4.29 million when varying part-time hours 
worked). CONCLUSIONS: Hemophilia involves costly life-long therapy, affecting 
the employability of patients and/or their families and imposing significant 
financial burden on society. Looking at new ways to support patients and 
families is essential in hemophilia care.  
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OBJECTIVES: Buprenorphine transdermal system therapy (BTDS) is indicated for 
the management of moderate to severe chronic pain when a continuous, 
around-the-clock opioid analgesic is needed for an extended period of time. This 
study assessed factors associated with medication persistence among patients 
initiating BTDS. METHODS: Patients aged >18 years initiating BTDS during 
January 1, 2011 - November 30, 2011 were identified in the IMS Private 
Practitioner Medical Claims database and IMS Pharmacy Claims database. The 
index date was defined as the first prescription of BTDS. Demographics, 
Charlson Comorbidity Index (CCI) and prior medication use were assessed in the 
pre-index 6-month period. Persistence was measured as the duration of BTDS 
prior to the first 28-day refill gap in the post-index 6-month period. Cox 
proportional hazards models were run to assess predictors of BTDS persistence 
controlling for demographics, CCI, and prior and 30-day concomitant drug use. 
RESULTS: The study included 10,457 patients newly treated with BTDS. Patients’ 
mean age was 55 years (±15); 30% were male and the mean CCI was 1 (±1.4). Prior 
to the index BTDS prescription 92%, 35% and 59% of the patients used opioids, 
NSAIDs and neuropathic pain agents, respectively. Multivariate regression 
analyses showed that patients with prior opioid and neuropathic pain agent use 
were 20% and 5% less likely to discontinue BTDS (p<0.05), respectively as 
compared to patients not using these agents. Patients with concomitant use of 
neuropathic pain agents were 15% less likely to discontinue therapy (p<0.01) as 
compared to patients without concomitant use of neuropathic pain agents. 
Sensitivity analyses with 30-day prior opioid use and including patients with ≥2 
claims of BTDS confirmed these findings. CONCLUSIONS: Prior and concomitant 
use of neuropathic pain agents and prior use of opioids were associated with 
significantly longer persistence among patients initiating BTDS. These data help 
to characterize the patient population treated with BTDS.  
 
PSY53  
IMPACT OF DOSAGE STRENGTH ON MEDICATION PERSISTENCE  
AMONG PATIENTS TREATED WITH BUPRENORPHINE TRANSDERMAL  
SYSTEM  
Pergolizzi J1, BenJoseph R2, Chang CL3, Pierz K2, Shah D2, Hess G3 
1Johns Hopkins University, Naples, FL, USA, 2Purdue Pharma L.P., Stamford, CT, USA, 3IMS 
Health Incorporated, Plymouth Meeting, PA, USA  
OBJECTIVES: Buprenorphine transdermal system (BTDS) is indicated for  
the management of moderate to severe chronic pain when a continuous, 
around-the-clock opioid analgesic is needed for an extended period of time. The 
purpose of this study was to assess medication persistence in patients on BTDS 
across varying dose strengths and in patients who had a dose change. 
METHODS: Patients aged >18 years initiating BTDS during 1/1/2011-11/30/2011 
were identified in the IMS Private Practitioner Medical Claims database and IMS 
Pharmacy Claims database. The index date was defined as the first prescription 
of BTDS. Medication persistence, dose change and final dose strength were 
assessed in the post-index 6-month period. Persistence was defined as the 
duration of BTDS therapy prior to the 1st28-day refill gap. Descriptive statistics, t-
tests and ANOVA were used to compare differences in persistence across  
patient cohorts. RESULTS: The study included 10,457 patients newly treated with 
BTDS. Medication persistence was significantly higher across patients receiving 
higher final doses (49.1 days (n=3,769), 69.2 days (n=4,463) and 97 days (n=2,225) 
for 5mcg/hr, 10 mcg/hr and 20 mcg/hr doses, respectively, p<0.0001). 
Additionally, persistence for patients who had a dose change (n=3,297) was 111.4 
days, compared to 47.8 days for those who did not (p<0.0001). Sensitivity 
analyses on patients with ≥2 BTDS claims (n=5,444) showed that patients on final 
dose strength 10 mcg/hr and 20 mcg/hr had 8.9 days and 19.2 days longer 
persistence when compared to patients on 5 mcg/hr (p<0.0001). Also, among 
patients with ≥2 BTDS claims, persistence was, on average, 17.1 days longer  
for patients who had a dose change compared to patients who did not (p<0.0001). 
CONCLUSIONS: BTDS persistence was longer among patients with higher final 
dose strengths and who had a dose change. Management of BTDS dosage  
over time and appropriate dose titration may impact persistence on BTDS 
therapy.  
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OBJECTIVES: The 19 item Compliance-Questionnaire-Rheumatology (CQR) is an 
open access questionnaire that was developed by Rheumatologists in the 
Netherlands, to predict the potential for non-adherence specifically in 
rheumatology patients. It was validated against gold standard compliance 
measures. The questionnaire item bank came from home and focus group 
patient interviews. Responses are provided on a 4 point Likert scale delineated 
by strength of agreement. METHODS: Patients self-reporting a diagnosis of 
rheumatoid arthritis (RA) and residing in the United States completed a self-
administered, internet-based questionnaire in the Fall of 2011, which included 
the CQR. CQR data were analysed using an automated analytical tool provided by 
the developers. Based on the validation paper, individual raw CQR questions are 
weighted to produce adjusted total summary scores for each patient, which can 
then be compared to validated cutoff values for specified levels of desired 
compliance ranging from 50-95%, to establish whether the patient is or is not 
likely to be non-compliant. Different weights exist depending on whether the 
user is interested in the potential for “dosing” compliance (the percentage of 
days the correct number of doses were taken) or dose “taking” compliance (the 
percentage of prescribed doses taken). RESULTS: Survey respondents were 76.2% 
female, 86.2% Caucasian, with mean age 56.4 years. At the 90%, 80%, and 50% 
minimum thresholds for “dosing” compliance, 99.2%, 83.8% and 66.1% of patients 
were identified as potentially non-compliant respectively. CONCLUSIONS: 
Depending on desired compliance thresholds, at least 60% of self-reported RA 
patients demonstrate attributes identifying them as potentially non-compliant 
with treatment. This instrument may be useful in streaming patients into 
adherence programs, identifying appropriate patients for specific treatments or 
improving patient/physician discourse during shared decision making 
discussions. Future work should look at validating against other common 
adherence measures and fine tuning patient attributes most likely to lead to 
non-compliance.  
 
PSY55  
HOW COMPLIANCE IS MEASURED IN TRANSPLANT PATIENTS TAKING 
IMMUNOSUPPRESSIVE AGENTS: A SYSTEMATIC LITERATURE REVIEW  
Baker TM1, Kiss N2, Fortier KJ2, Sidhu M2 
1Oxford Outcomes, Bethesda, MD, USA, 2Oxford Outcomes, Morristown, NJ, USA  
OBJECTIVES: Non-adherence to medication is one of the biggest issues in health 
care today, where roughly half of all prescriptions for drugs to be taken on  
an ongoing basis are either not completed or are never even filled. Non-
adherence can lead to increased rates of AEs and increased cost of care; thus, 
adherence to medication may impact the effectiveness of a product in the real-
world. This is especially relevant for transplant patients, where the 
consequences of non-adherence can increase the risk of acute rejections. Despite 
this concern, information on transplant patient medication adherence is  
still uncommon, and a standard measure of adherence is not available. Our 
objective was to examine the existing literature to assess what adherence 
measures are implemented and whether they are implemented routinely. 
METHODS: A systematic review of peer-reviewed literature was conducted  
to identify RCTs and observational studies that measured compliance in 
transplant patients taking immunosuppressive agents. We searched Embase and 
Medline for studies from 2008-present in which adherence, compliance, or 
persistence appeared in the title, abstract, or as an index term. RESULTS: The 
search identified 46 studies, of which 11 measured adherence. Methods of 
measuring compliance varied among the included studies, some of which used 
multiple measurements: Basel Assessment of Adherence Scale to 
Immunosuppressives, 2; Medication Event Monitoring System, 2; blood test, 3; 
self-report, 2; VAS, 1; Likert scale, 1; pill counts, 1; questionnaire, 1; continuous 
measures of medication adherence, 1; measure not specified in remaining 
studies. In most studies, the patient, not physicians, assessed their own 
compliance. CONCLUSIONS: Adherence to medication in transplant patients is 
neither measured regularly nor in a consistent manner. All studies of transplant 
patients should assess medication adherence, and further studies must be 
conducted to discern a single reliable and economical measurement of 
compliance in transplant patients.  
